103 related articles for article (PubMed ID: 18557488)
1. Destroying malignant white cells.
Baum MS
J N J Dent Assoc; 2008; 79(1):18-9. PubMed ID: 18557488
[No Abstract] [Full Text] [Related]
2. Is LukS-PV a novel experimental therapy for leukemia?
Shan W; Ma X; Deng F
Gene; 2017 Feb; 600():44-47. PubMed ID: 27916717
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
FitzGerald DJ; Wayne AS; Kreitman RJ; Pastan I
Cancer Res; 2011 Oct; 71(20):6300-9. PubMed ID: 21998010
[TBL] [Abstract][Full Text] [Related]
4. Targeted toxins.
Frankel AE; Kreitman RJ; Sausville EA
Clin Cancer Res; 2000 Feb; 6(2):326-34. PubMed ID: 10690507
[TBL] [Abstract][Full Text] [Related]
5. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
[TBL] [Abstract][Full Text] [Related]
6. Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
Yurkiewicz IR; Coutre S; Ghesquieres H; Pastan I; Kreitman RJ
Leuk Lymphoma; 2021 Nov; 62(11):2812-2814. PubMed ID: 34030585
[No Abstract] [Full Text] [Related]
7. RE: Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321 printing error.
Ding D
Neurol Res; 2011 May; 33(4):448. PubMed ID: 21535947
[No Abstract] [Full Text] [Related]
8. [Monoclonal antibodies in hematologic oncology].
Kuliczkowski K; Podolak-Dawidziak M
Pol Arch Med Wewn; 2002 May; 107(5):469-73. PubMed ID: 12189920
[No Abstract] [Full Text] [Related]
9. Combination effects of SC144 and cytotoxic anticancer agents.
Oshima T; Cao X; Grande F; Yamada R; Garofalo A; Louie S; Neamati N
Anticancer Drugs; 2009 Jun; 20(5):312-20. PubMed ID: 19322070
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
11. [Prospects for the use of plant polysaccharides in complex treatment of malignant tumors].
Safonova EA; Razina TG; Zueva EP; Lopatina KA; Efimova LA; Gur'ev AM; Rybalkina OIu; Khotimchenko IuS
Eksp Klin Farmakol; 2012; 75(9):42-7. PubMed ID: 23156088
[TBL] [Abstract][Full Text] [Related]
12. Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies.
Fernández A; De Arriba F; Rivera J; Heras I; Vicente V; Lozano ML
Haematologica; 2008 Sep; 93(9):1436-8. PubMed ID: 18641021
[No Abstract] [Full Text] [Related]
13. Bacterial therapeutics.
Bentley S; Sebaihia M
Nat Rev Microbiol; 2007 Mar; 5(3):170-1. PubMed ID: 17310535
[No Abstract] [Full Text] [Related]
14. [Asparagus in asparaginase therapy?].
März W; Unger C
Med Monatsschr Pharm; 1999 Dec; 22(12):393. PubMed ID: 10628150
[No Abstract] [Full Text] [Related]
15. [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
Rukavitsyn OA; Pop VP
Ter Arkh; 2008; 80(7):80-4. PubMed ID: 18763606
[No Abstract] [Full Text] [Related]
16. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
17. The molecular perspective: L-asparaginase.
Goodsell DS
Oncologist; 2005 Mar; 10(3):238-9. PubMed ID: 15793227
[No Abstract] [Full Text] [Related]
18. Plasma leptin levels vary with the periods during chemotherapy.
Minami R; Muta K; Ilseung C; Matsushima T; Abe Y; Nishimura J; Nawata H
Am J Hematol; 2003 Oct; 74(2):145. PubMed ID: 14508806
[No Abstract] [Full Text] [Related]
19. The 8th annual meeting of CESAR in St. Gallen--novel therapeutic concepts in hemato-oncology.
Morant R; Sehrt D; Jaehde U
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):58-9. PubMed ID: 21176728
[No Abstract] [Full Text] [Related]
20. [Hematology: experiences with common national reports on new anti-cancer drugs].
Kristensen JS; Bukh A
Ugeskr Laeger; 2009 Mar; 171(13):1089. PubMed ID: 19321084
[No Abstract] [Full Text] [Related]
[Next] [New Search]
